Embla Medical hf.
OSSFF
Other OTC4.15
USD
- -
- -
ISIN
IS0000000040
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-12.63
76.60
5Y
-45.39
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Sveinn Solvason
- Full Time Employees
- 4,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Grjothals 1-5 Reykjavik Iceland
- IPO Date
- May 23, 2019
- Website
- emblamedical.com
- Similar Companies
- Business
- Embla Medical hf. Embla Medical hf. (OSSFF), founded in 1971 and headquartered in Reykjavik, Iceland, is a leading global provider of innovative non-invasive orthopedic products and mobility solutions, operating through three main segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care; the company serves healthcare providers, rehabilitation specialists, orthopedic and prosthetic clinics, hospitals, and patients worldwide across the Americas, Europe, Middle East, Africa, Asia-Pacific, and beyond. In Prosthetics and Neuro Orthotics, it offers mechanical and bionic products including lower- and upper-limb prosthetics, microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints under brands such as Össur, Fior & Gentz, and College Park; Bracing and Supports provides devices for spinal, hip, knee, foot, ankle, and hand support as well as injury solutions for fractures, post-operative care, and ligament injuries; Patient Care delivers prosthetics and orthotics for neurological, gait, and musculoskeletal conditions through the ForMotion clinic network spanning multiple countries. Embla Medical hf., formerly known as Össur hf., changed its name in April 2024 and established itself as a unified entity incorporating leading brands Össur, Fior & Gentz, College Park, and ForMotion while advancing its Growth'27 strategy focused on patient reach, innovative solutions, and O&P value creation. Recent major developments include the early 2024 acquisition of Fior & Gentz, a developer of lower-limb neuro orthotic devices that expanded capabilities in chronic mobility challenges and contributed to 9% local currency sales growth; in July 2025, it signed an agreement to acquire a 51% majority stake in Streifeneder ortho.production GmbH, a German orthotics firm, via issuance of 2.8 million new shares valued at DKK 93 million to strengthen presence in the world's second-largest O&P market, enhance full-range offerings, and realize commercial synergies. As a subsidiary of William Demant Invest A/S and listed on Nasdaq Copenhagen, Embla Medical hf. emphasizes sustainable growth, reporting record 2024 sales of USD 855 million, 6% organic growth, and 20% EBITDA margin before special items, with operations supported by approximately 4,000 employees and over 2,100 patents.
Embla Medical hf. (OSSUY) Q1 2026 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q3 2025 Earnings Call Transcript